Short-term Course of Intraocular Pressure after Intravitreal Injection of Triamcinolone Acetonide

Ophthalmology

Volumn 113, Issue 7, 2006, Pages 1174-1178

  Benz, Matthew S ^a   Albini, Thomas A ^a   Holz, Eric R ^a   Lakhanpal, Rohit R ^a   Westfall, Andrew C ^a   Iyer, Mohan N ^a   Carvounis, Petros E ^a  

^a CULLEN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCURY; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; TONOMETRY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL DISEASES; TONOMETRY, OCULAR; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 33745331095     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2005.10.061     Document Type: Article

References (21)

1. Challa J.K., Gillies M.C., Penfold P.L., et al. Exudative macular degeneration and intravitreal triamcinolone. 18 month follow up. Aust N Z J Ophthalmol 26 (1998) 277-281
2. Spaide R.F., Sorenson J., and Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112 (2005) 301-304
3. Danis R.P., Ciulla T.A., Pratt L.M., and Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20 (2000) 244-250
4. Martidis A., Duker J.S., Greenberg P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109 (2002) 920-927
5. Jonas J.B., Akkoyun I., Kreissig I., and Degenering R.F. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide. a comparative, non-randomised study. Br J Ophthalmol 89 (2005) 321-326
6. Ip M.S., Gottlieb J.L., Kahana A., et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 122 (2004) 1131-1136
7. Jonas J.B., Akkoyun I., Kamppeter B., et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 19 (2005) 65-71
8. Flynn Jr. H.W., and Scott I.U. Intravitreal triamcinolone acetonide for macular edema associated with diabetic retinopathy and venous occlusive disease. it's time for clinical trials. Arch Ophthalmol 123 (2005) 258-259
9. Singh I.P., Ahmad S.I., Yeh D., et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 138 (2004) 286-287
10. Jonas J.B., Kreissig I., and Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 87 (2003) 24-27
11. Smithen L.M., Ober M.D., Maranan L., and Spaide R.F. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138 (2004) 740-743
12. Gillies M.C., Simpson J.M., Billson F.A., et al. Safety of an intravitreal injection of triamcinolone. results from a randomized clinical trial. Arch Ophthalmol 122 (2004) 336-340
13. Cekic O., Chang S., Tseng J.J., et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 139 (2005) 993-998
14. Benz M.S., Murray T.G., Dubovy S.R., et al. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 121 (2003) 271-273
15. Moshfeghi D.M., Kaiser P.K., Scott I.U., et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 136 (2003) 791-796
16. Westfall A.C., Osborn A., Kuhl D., et al. Acute endophthalmitis incidence. intravitreal triamcinolone. Arch Ophthalmol 123 (2005) 1075-1077
17. Aiello L.P., Brucker A.J., Chang S., et al. Evolving guidelines for intravitreous injections. Retina 24 suppl (2004) S3-S19
18. Dwinger M.C., Pieper-Bodeewes I., Eter N., and Holz F.G. Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection. [in German]. Klin Monatsbl Augenheilkd 222 (2005) 638-642
19. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
20. Rosenfeld P.J., Schwartz S.D., Blumenkranz M.S., et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112 (2005) 1048-1053
21. Moshfeghi A.A., Scott I.U., Flynn Jr. H.W., and Puliafito C.A. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 138 (2004) 489-492